IHPBA President | Prof. René Adam and Academician Xiaoping Chen：Strengthening Friendships and Enhancing Cooperation – Expanding the Vision of the International Hepato-Pancreato-Biliary Association (IHPBA) in China

IHPBA President | Prof. René Adam and Academician Xiaoping Chen：Strengthening Friendships and Enhancing Cooperation – Expanding the Vision of the International Hepato-Pancreato-Biliary Association (IHPBA) in China

From October 25 to 28, 2024, Wuhan hosted an enriching academic exchange – the 9th Academic Symposium of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (CCIHPBA), alongside the symposium commemorating the 110th birth anniversary of Academician Fazu Qiu and a tribute to Academician Yunyi Liu. Oncology Frontier, invited Prof. René Adam, current President of IHPBA from AP-HP Paul Brousse Hospital in Paris, France, and Academician Xiaoping Chen, President of the CCIHPBA from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, to share insights on IHPBA's mission and the establishment and development of its Chinese chapter.
The 2024 Jiangsu Hematology Physicians Association Conference Highlights Advancements in Standardized Diagnosis and Treatment of Hematologic diseases

The 2024 Jiangsu Hematology Physicians Association Conference Highlights Advancements in Standardized Diagnosis and Treatment of Hematologic diseases

From October 18 to 20, 2024, the 2024 Jiangsu Hematology Physicians Association Academic Conference was held in Taizhou, Jiangsu Province, focusing on the standardized diagnosis and treatment of hematologic diseases. Organized by the Jiangsu Hematology Physicians Association and hosted by the Affiliated Taizhou People’s Hospital of Nanjing Medical University and The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), the conference provided a high-level academic exchange platform. Hematology Frontier invited Dr. Jianyong Li, Chairman of the conference and a distinguished expert from Jiangsu Provincial People’s Hospital, to share his insights on the event’s key highlights and discuss the current and future directions of hematology in China.
Professor Owen O’Connor and Professor Zhengzi Qian Review the Current Status and Latest Advances in the Treatment of R/R PTCL

Professor Owen O’Connor and Professor Zhengzi Qian Review the Current Status and Latest Advances in the Treatment of R/R PTCL

The 5th Tianjin International Lymphoma Academic Conference, as an academic platform to promote international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and cooperation in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Professor Owen O’Connor, President of the Lymphoma Alliance and from the University of Virginia Cancer Center, and Professor Zhengzi Qian from the Tianjin Medical University Cancer Hospital to engage in a dialogue between China and the rest of the world, reviewing the current status and latest advances in the treatment of relapsed/refractory peripheral T-cell lymphoma (R/R PTCL).
ASCO GI | Dr. Pashtoon M. Kasi: ctDNA Proven to Guide Adjuvant Chemotherapy in Colorectal Cancer

ASCO GI | Dr. Pashtoon M. Kasi: ctDNA Proven to Guide Adjuvant Chemotherapy in Colorectal Cancer

Despite ctDNA’s nascent role in treatment decision-making, it is a proven marker of MRD in CRC patients, and research increasingly explores its role in guiding treatment across gastrointestinal cancers. At the 2024 ASCO Gastrointestinal Cancers Symposium, Dr. Pashtoon M. Kasi from Weill Cornell Medicine and Dr. Jeanne Tie from the Peter MacCallum Cancer Centre presented findings from two clinical trials investigating ctDNA in CRC adjuvant chemotherapy guidance.
ASCO 2024 | Dr. Shaalan Beg: Breakthrough Study on Thermal Ablation for Small Colorectal Liver Metastases

ASCO 2024 | Dr. Shaalan Beg: Breakthrough Study on Thermal Ablation for Small Colorectal Liver Metastases

At the 2024 ASCO Annual Meeting, a groundbreaking study led by Dr. Martijn Ruben Meijerink from Amsterdam University Medical Center focused on thermal ablation versus surgery for small colorectal liver metastases. This study has the potential to change clinical practice. Dr. Shaalan Beg from the Simmons Comprehensive Cancer Center at the University of Texas Southwestern Medical Center recently shared his insights on this noteworthy research in ASCO Daily News. This article presents the study’s key findings and its implications in the medical field.
Dr. Salomon Manier: Navigating the Medical Seas, Innovating and Upgrading Treatment Plans for TIE-NDMM Patients

Dr. Salomon Manier: Navigating the Medical Seas, Innovating and Upgrading Treatment Plans for TIE-NDMM Patients

Recently, the 11th Sino-French Hematology Academic Conference of the Chinese Medical Doctor Association was successfully held in Tianjin, attracting hundreds of domestic and international authoritative experts and scholars in the field of hematology. During the conference, "Hematology Frontier" specially invited Dr. Salomon Manier from the Hematology Department of Lille University Hospital in France to discuss the current treatment challenges, emerging treatment plans, and management in the elderly and frail patient population for patients with transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM).
ASCO GI 2024 | Dr. Zhi Peng Discusses Immunotherapy and Targeted Chemotherapy for Gastric Cancer

ASCO GI 2024 | Dr. Zhi Peng Discusses Immunotherapy and Targeted Chemotherapy for Gastric Cancer

The 2024 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2024) took place in San Francisco from January 18-20, gathering top experts from around the world to share the latest advances in gastrointestinal cancer research. Dr. Zhi Peng from Peking University Cancer Hospital presented two studies (Abstracts 312 and 317) in the poster session, showcasing the contributions of Chinese researchers on the international stage. In an exclusive interview with Oncology Frontier, Professor Peng shared insights on his studies and perspectives on gastric cancer diagnosis and treatment.
ASCO Plenary Series | Dr. Ruihua Xu and Dr. Florian Lordick: FRUTIGA Study Offers New Hope for Second-Line Treatment of Advanced Gastric Cancer

ASCO Plenary Series | Dr. Ruihua Xu and Dr. Florian Lordick: FRUTIGA Study Offers New Hope for Second-Line Treatment of Advanced Gastric Cancer

The field of second-line treatment for advanced gastric cancer is a current focal point in oncology research. On February 6, 2024, during the ASCO Plenary Series, Dr. Ruihua Xu from Sun Yat-sen University Cancer Center presented findings from the FRUTIGA study (NCT03223376), a phase III trial conducted in China evaluating the efficacy of fruquintinib combined with paclitaxel for second-line treatment in advanced gastric cancer. The study offers an additional treatment option for advanced gastric cancer. Oncology Frontier highlighted perspectives from Dr. Ruihua Xu and Dr. Florian Lordick, Director of the University Cancer Center Leipzig, on the significance of FRUTIGA. Here’s a summary of the discussion.
SIBCS| Dr. Virginia Kaklamani’s Insights on Post-CDK4/6i Management of HR+ Advanced Breast Cancer at MD Anderson

SIBCS| Dr. Virginia Kaklamani’s Insights on Post-CDK4/6i Management of HR+ Advanced Breast Cancer at MD Anderson

On October 18, 2024, the 18th National Breast Cancer Conference and the 19th Shanghai International Breast Cancer Forum grandly opened, gathering significant global advancements in breast cancer. In the era following CDK4/6 inhibitors for hormone receptor-positive (HR+) breast cancer, targeted endocrine therapies based on the PIK3CA/AKT1/PTEN pathway have brought new hope to patients. At this conference, Dr. Virginia Kaklamani from The University of Texas MD Anderson Cancer Center shared important insights on the progress of treating HR+ metastatic breast cancer and discussed post-CDK4/6 inhibitor strategies and clinical practice experiences for HR+ advanced breast cancer in the "Viewpoint · SIBCS Special" column of Oncology Horizon.
Dr. Benlong Yang: New Frontiers in Breast Reconstruction – Prevention and Management of Implant Complications

Dr. Benlong Yang: New Frontiers in Breast Reconstruction – Prevention and Management of Implant Complications

Breast reconstruction surgery offers hope for patients to regain confidence and beauty in the field of breast cancer treatment. With advances in medical technology, implant-based breast reconstruction has become a mainstream choice. However, complications related to implants remain a key concern for both surgeons and patients. At the 16th Shanghai Breast Reconstruction Conference, Dr. Benlong Yang from the Breast Surgery Department of Fudan University Shanghai Cancer Center led a session discussing "Implant Complications." Following the event, Oncology Frontier interviewed Dr. Yang to delve into key issues surrounding implant reconstruction.